NCT00099346终止1 期
A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
研究概览
简要总结
Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In Part I, patients who are at least 18 years of age with advanced solid tumors and colorectal cancer will be eligible for the first part of this study. Patient must have recovered from and be at least 3 weeks from previous cancer treatment.
- •In Part II, only patients with colorectal cancer will be eligible to participate. The patients may have received up to 3 prior treatments for their colorectal cancer. Patients must have recovered from and be at least 3 weeks from previous therapy.
排除标准
- •Patients who have had treatment with any investigational drug within the past 30 days.
- •Patients who have certain types of blood cancers such as leukemia or lymphoma.
- •Patients who have uncontrolled congestive heart failure (CHF), chest pain, or heart attack within the past 3 months.
- •Patient is pregnant or nursing.
研究者
相似试验
已完成
2 期
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX AloneMetastatic Colorectal CancerNCT00890305Medivation, Inc.171
终止
1 期
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaSolid TumorsNon-Hodgkins LymphomaPancreatic Neuroendocrine TumorsMultiple MyelomaPNETNHLNCT02110563Dicerna Pharmaceuticals, Inc., a Novo Nordisk company50
已完成
不适用
Validation study of colorectal cancer treatment effect prediction by metabolomic markersColorectal cancerJPRN-UMIN000037904Keio University school of medicine44
招募中
1 期
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCNon Small Cell Lung CancerNCT05430386Jiangsu Hansoh Pharmaceutical Co., Ltd.174
终止
1 期
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT02314052Dicerna Pharmaceuticals, Inc., a Novo Nordisk company21